SLXN · Silexion Therapeutics Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| R&D | $1.37M | - | $2.16M | $1.02M | $961.0K | - | $3.22M | $766.0K |
| SG&A | $1.38M | - | $1.14M | $1.27M | $289.0K | - | $4.82M | $179.0K |
| Total Operating Expenses | $2.75M | - | $3.29M | $2.28M | $1.25M | - | $731.0K | $1.39M |
| D&A | $2.0K | - | $4.0K | $3.0K | $8.0K | - | $22.0K | $7.0K |
| Operating Income | ($2.75M) | - | ($3.29M) | ($2.28M) | ($1.25M) | - | ($8.04M) | ($1.41M) |
| Interest Expense | - | - | - | - | - | - | - | - |
| Income Tax | - | - | $0 | $3.0K | $5.0K | - | $6.0K | $2.0K |
| Net Income | ($2.73M) | - | ($3.26M) | ($2.50M) | ($1.42M) | - | ($809.0K) | ($1.49M) |
| EPS - Basic | $8.50 | - | $28.80 | $43.20 | $1843.50 | - | $2740.50 | $7924.50 |
| EPS - Diluted | $8.50 | - | $28.80 | $43.20 | $1843.50 | - | $2740.50 | $7924.50 |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.41M | $5.99M | $9.24M | $3.47M | $6.15M | $1.19M | $1.97M | $4.59M |
| Accounts Receivable | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - |
| Accounts Payable | $787.0K | $787.0K | $946.0K | $692.0K | $722.0K | $929.0K | $799.0K | $319.0K |
| Current Assets | $4.07M | $6.64M | $11.05M | $5.24M | $7.72M | $2.25M | $3.05M | $4.98M |
| Total Assets | $4.60M | $7.21M | $11.61M | $5.80M | $3.58M | $2.86M | $3.09M | $2.52M |
| Current Liabilities | $4.06M | $2.76M | $2.79M | $2.15M | $2.40M | $3.52M | $3.58M | $2.20M |
| Long-term Debt | - | - | - | - | - | - | - | - |
| Total Liabilities | $4.31M | $4.61M | $4.64M | $5.68M | $5.72M | $6.85M | $7.67M | $2.37M |
| Stockholders' Equity | $291.0K | $2.60M | $6.98M | $120.0K | $2.59M | ($3.99M) | ($4.58M) | ($15.48M) |
| Retained Earnings | ($57.90M) | ($55.17M) | ($50.75M) | ($47.49M) | ($44.99M) | ($43.25M) | ($41.58M) | ($29.66M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.65M) | - | ($2.84M) | ($2.51M) | ($1.75M) | - | ($2.65M) | ($1.06M) |
| Investing Cash Flow | $0 | - | $0 | $0 | ($6.0K) | - | ($16.0K) | ($2.0K) |
| Financing Cash Flow | $83.0K | - | $8.62M | ($195.0K) | $7.43M | - | $0 | $522.0K |
| CapEx | $0 | - | $0 | $0 | $6.0K | - | $6.0K | $2.0K |
| Free Cash Flow | ($3.65M) | - | ($2.84M) | ($2.51M) | ($1.76M) | - | ($2.66M) | ($1.07M) |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross margin | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - |
| FCF / Net income | 1.33 | - | 0.87 | 1.00 | 1.24 | - | 3.29 | 0.72 |
| R&D / Revenue | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - |
| Return on assets | -59.4% | - | -28.1% | -43.2% | -39.7% | - | -26.2% | -59.0% |
| Return on equity | -939.2% | - | -46.8% | -2085.8% | -55.0% | - | 17.7% | 9.6% |
| Return on invested capital | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||
| Current ratio | 1.00 | 2.41 | 3.97 | 2.44 | 3.22 | 0.64 | 0.85 | 2.27 |
| Quick ratio | 1.00 | 2.41 | 3.97 | 2.44 | 3.22 | 0.64 | 0.85 | 2.27 |
| Cash ratio | 0.59 | 2.17 | 3.32 | 1.61 | 2.57 | 0.34 | 0.55 | 2.09 |
| Leverage | ||||||||
| Debt / Equity | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - |
| Equity multiplier | 15.81 | 2.77 | 1.66 | 48.31 | 1.39 | -0.72 | -0.67 | -0.16 |
| Liabilities / Assets | 0.94 | 0.64 | 0.40 | 0.98 | 1.60 | 2.39 | 2.48 | 0.94 |
| Efficiency | ||||||||
| Asset turnover | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - |
| Valuation | ||||||||
| P / E | 0.2x | - | 1.2x | 2.8x | 0.1x | - | 0.0x | 0.2x |
| P / B | 14.2x | - | 5.5x | 586.8x | 7.1x | - | - | - |
| P / S | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| Growth | ||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -119.9% | - | 59.0% | -61.5% | - | - | - | - |
| Net income growth (YoY) | -92.1% | - | -303.2% | -68.1% | - | - | - | - |
| EPS growth (YoY) | -99.5% | - | -98.9% | -99.5% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -107.4% | - | -6.9% | -135.0% | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -88.7% | - | - | - | - | - | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Silexion Therapeutics Corp against the 5 most active filers in the same SIC group.